CRMD

CorMedix Inc. is a biotechnology company listed in the healthcare sector with a market capitalization of $960.44 million and approximately 64 employees. The company's revenue for the trailing twelve months (TTM) stands at $214.30 million. Financially, CorMedix has demonstrated high profitability, with a gross margin of 94.3%, operating margin of 49.2%, and profit margin of 75.8%. The company's returns on equity and assets are also notable at 75.1% and 15.7%, respectively. Additionally, the debt-to-equity ratio is 39.80, indicating a substantial amount of debt. CorMedix has $55.72 million in cash and $148.92 million in debt. The company's valuation metrics include a price-to-earnings (P/E) ratio of 5.52 (TTM), forward P/E of 4.88, and a price-to-book of 2.55. Revenue growth has been significant at 810.2% year-over-year, although earnings growth is not available for comparison.